Search research articles
Contact Us
Filters
Showing results (571-580 of 601) with videos related to
Page
of 61
Sort By:
The Oncologist
|
March 11, 2022
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
J Connor Wells, Aven Sidhu, Keyue Ding, et al.
Cancer
|
October 16, 2013
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial
Jolie Ringash, Heather-Jane Au, Lillian L Siu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 1, 2023
The Feasibility of Quality Assurance in the TOPGEAR International Phase 3 Clinical Trial of Neoadjuvant Chemoradiation Therapy for Gastric Cancer (an Intergroup Trial of the AGITG/TROG/NHMRC CTC/EORTC/CCTG)
Jelena Lukovic, Alisha J Moore, Mark T Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
Daniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
Clinical Colorectal Cancer
|
September 13, 2023
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer
Di Maria Jiang, Shruti Parshad, Luna Zhan, et al.
The New England Journal of Medicine
|
August 31, 2012
Intermittent androgen suppression for rising PSA level after radiotherapy
Juanita M Crook, Christopher J O'Callaghan, Graeme Duncan, et al.
Cancer Research
|
August 17, 2002
CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3
Marina Kochetkova, Olivia L D McKenzie, Anthony J Bais, et al.
JAMA Network Open
|
December 5, 2023
Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial
Eric X Chen, Jonathan M Loree, Emma Titmuss, et al.
The Lancet. Gastroenterology & Hepatology
|
February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2012
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17
M M Vickers, C S Karapetis, D Tu, et al.
Page
of 61
Search research articles
Search
Showing results (571-580 of 601) with videos related to
Sort By:
Page
of 61
The Oncologist
|
March 11, 2022
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
J Connor Wells, Aven Sidhu, Keyue Ding, et al.
Cancer
|
October 16, 2013
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial
Jolie Ringash, Heather-Jane Au, Lillian L Siu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 1, 2023
The Feasibility of Quality Assurance in the TOPGEAR International Phase 3 Clinical Trial of Neoadjuvant Chemoradiation Therapy for Gastric Cancer (an Intergroup Trial of the AGITG/TROG/NHMRC CTC/EORTC/CCTG)
Jelena Lukovic, Alisha J Moore, Mark T Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
Daniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
Clinical Colorectal Cancer
|
September 13, 2023
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer
Di Maria Jiang, Shruti Parshad, Luna Zhan, et al.
The New England Journal of Medicine
|
August 31, 2012
Intermittent androgen suppression for rising PSA level after radiotherapy
Juanita M Crook, Christopher J O'Callaghan, Graeme Duncan, et al.
Cancer Research
|
August 17, 2002
CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3
Marina Kochetkova, Olivia L D McKenzie, Anthony J Bais, et al.
JAMA Network Open
|
December 5, 2023
Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial
Eric X Chen, Jonathan M Loree, Emma Titmuss, et al.
The Lancet. Gastroenterology & Hepatology
|
February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2012
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17
M M Vickers, C S Karapetis, D Tu, et al.
Page
of 61